Sanofi-sponsored Scientific Abstracts and Presentations from the American Diabetes Association (ADA) 80th Annual Scientific Sessions

A Virtual Experience

June 12-16, 2020

Insulin glargine U300

1028-P: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Insulin-Naïve Patients with Type 2 Diabetes (T2DM): Interim Analysis of the ATOS Study

G. Galstyan, A. Bhansali, H. Vargas-Uricoechea, A. Tirosh, G. Sun, M. Naqvi, V. Pilorget, M. Coudert, D. Cherkasov, N. Khan

1035-P: Real-World Safety and Effectiveness of Insulin Glargine 300 U/mL (Gla-300) in People with Type 2 Diabetes (T2DM) Who Fast During Ramadan: Regional Analysis of the ORION Study

M. Hassanein, M. Buyukbese, R. Malek Sr., V. Pilorget, M. Naqvi, B. Berthou, I. Shaltout, R. Sahay

1038-P: Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation Standard-of-Care Basal Insulin Analogs (SOC-BI) in Insulin-Naïve Patients with Type 2 Diabetes (T2D): Impact of Renal Function on the Outcomes of the Randomized Pragmatic Real-Life ACHIEVE Control Study

L. Meneghini, A. Cheng, P. Evenou, J. Gill, A. Mohamed, G. Umpierrez

2192-PUB: Treatment Satisfaction in People with Type 2 Diabetes (T2D) Receiving Basal Insulin (BI): Results from Real-World Studies and Randomized Controlled Trials (RCTs) with Insulin Glargine 300 U/mL (Gla-300)

S.B. Harris, F. Snoek, L. Meneghini, F. Lauand, J. Westerbacka, A. Roborel de Climens, K. Khunti

Back to top

Insulin glargine U100/lixisenatide 33 mcg/mL

88-LB: Similar Efficacy and Safety of iGlarLixi When Initiated in Patients with Type 2 Diabetes (T2D) with or without Concomitant Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Use in a Randomized Controlled Trial (RCT) and Real-World Setting

J. Rosenstock, A. Ali, J. Meier, F. Giorgino, C. Guja, M. Prázný, R. Lubwama, E. Souhami, L. Blonde

959-P: Indirect Treatment Comparison (ITC) of iGlarLixi vs. IDegLira in Adults Inadequately Controlled by GLP-1 Receptor Agonists (GLP-1RAs)

P. Home, V.R. Aroda, M.S. Fazeli, C. Whittington, H. Goswami, A. Shaunik, M-M. Pourrahmat, L. Blonde, S. Kalra

Back to top

Insulin glargine U100

1048-P: Fasting C-Peptide as a Predictor for Hypoglycemia Risk and HbA1c Reduction in Chinese T2DM Patients Switching from Premixed to Basal Insulin: A Post Hoc Analysis from the Optimization Study

W. Yang, P. Ruan, X. Zhang, N. Cui

2198-PUB: The Impact of Basal Insulin Initiation to Background Sulfonylurea Treatment on Hypoglycemia Occurrence: Evaluation of the Balkan Cohort of the DUNE Study

A. Janež, M. Lunder, M. Janić, N. Grulovic, D. Zdravkovic, A. Jotic, K. Lalic, N. Lalic

Back to top

Lixisenatide

1066-P: Comparison of Efficacy of Lixisenatide Combined with Basal Insulin with or without Metformin in Asian and Caucasian Patients with Type 2 Diabetes: A Pooled Analysis of Phase III Studies

R. Yuezhong, M. Liu, G. Wu, X. Zhang, N. Cui

1421-P: The Impact of Blood Pressure on Risk of Death is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event

M.O. Wijkman, B. Claggett, R. Diaz, H.C. Gerstein, A. Kober, E. Lewis, A.P. Maggioni, E. Wolsk, D. Aguilar, R. Bentley-Lewis, J.J. McMurray, J.L. Probstfield, M.C. Riddle, J.C. Tardif, S. Solomon, M.A. Pfeffer

Back to top

Diabetes management

T1 Diabetes

851-P: Technology Use by Age and Region in Adults with Type 1 Diabetes (T1D) in the SAGE Study

S. Edelman, D. Bruttomesso, K. Close, A.G.D. Vianna, F. Lauand, S. Brette, E. Renard

1514-P: Suboptimal Glycemic Control and High Prevalence of Diabetes Complications in Adults with Type 1 Diabetes (T1D) in the SAGE Study

E. Renard, Z. Bosnyak, F. Lauand, P. Pozzilli, H. Ikegami, J. Kesavadev, A.G.D. Vianna

1625-P: Association of Patient- and Disease-Related Factors with Glycemic Target Achievement in Type 1 Diabetes (T1D) in the SAGE Study

J. Seufert, H. Ikegami, S. Brette, V. Pilorget, F. Lauand, E.G. Wilmot, E. Renard, J.J. Gagliardino

1626-P: Differences in Patient-Reported Outcomes (PROs) by Age and Region in Adults with Type 1 Diabetes (T1D) in the SAGE Study

L. Berard, F.J. Ampudia-Blasco, S. Brette, D. Bruttomesso, K. Close, H. Ikegami, D. Jurišić-Eržen, F. Lauand, A. Peters, V. Pilorget, B. Ramanathan, E. Renard, E.G. Wilmot, A. Roborel de Climens

1627-P: Real-World Comparison of Acute Complications in Adult Patients with Type 1 Diabetes in US and European Registries

F.L. Zhou, J. Grimsmann, J. Pettus, W. Kerner, K. Miller, L. Stechemesser, S. Edeman, A.M. Ibald-Mulli, R.W. Holl

1629-P: Association of Patient-Reported Outcomes (PROs) Scores with Glycemic Target Achievement in Type 1 Diabetes (T1D) in the SAGE Study

E.G. Wilmot, F.J. Ampudia-Blasco, L. Berard, S. Brette, L.E. Calliari, E. Fitts, K. Close, J.J. Gagliardino, F. Lauand, A. Peters, E. Renard, A. Roborel de Climens, J. Seufert

T2 Diabetes

19-LB: Treatment Intensification and Risk of Cardiovascular Events in Insulin-Treated Patients with Type 2 Diabetes: A United Kingdom Retrospective Cohort Study

M. Adan, S. Seidu, K. Khunti, F. Zaccardi, C.L. Gillies, D. Webb, R. Lubwama, A.H. Boss, T.A. Dex

965-P: Real-World Evidence of the Effect on Glycemic Control with Relatively Simultaneous vs. Sequential Initiation of Basal Insulin and GLP-1 Receptor Agonists

J. Rosenstock, F. Ampudia-Blasco, R. Lubwama, X.V. Peng, A.H. Boss, L. Shi, V. Fonseca

1029-P: Effectiveness of Premix Insulin (Premix) in Type 2 Diabetes (T2D): A Retrospective UK Cohort Study

E.B. Jude, A. Ali, R. Emral, N. Nanda, R. Lubwama, K.D. Palmer, A. Shaunik, P. Raskin, F. Gómez Peralta, C. Trescoli

1582-P: Glycemic Change from Baseline in the First Large-Scale Longitudinal Nationwide Study on Management and Real-World Outcomes of Diabetes in India (LANDMARC)

R. Ghosh, A.K. Das, A. Mithal, S. Joshi, K.M. Prasanna Kumar, S. Kalra, A. Gopalakrishnan Unnikrishnan, H. Thacker, B. Sethi, S. Mohanasundaram, S.K. Menon, A. Nair, N. Rais, S. Kumar Wangnoo, S. Chowdhury, A.H. Zargar

1588-P: Therapy Trends in Initial 6 Months of the First Large-Scale Longitudinal Nationwide Study on Management and Real-World Outcomes of Diabetes in India (LANDMARC)

R. Ghosh, A.K. Das, A. Mithal, S. Joshi, K.M. Prasanna Kumar, S. Kalra, A. Gopalakrishnan Unnikrishnan, H. Thacker, B. Sethi, S. Mohanasundaram, S.K. Menon, A. Nair, N. Rais, S. Kumar Wangnoo, S. Chowdhury, A.H. Zargar

2232-PUB: Reasons for Treatment Discontinuation in Type 2 Diabetes (T2D): Results from an Online Patient Survey in the UK and US

A. Roborel de Climens, E. Pain, A.H. Boss, A. Shaunik

2258-PUB: Impact of Cardiovascular (CV) Risk Factors During the Initial 6 Months of the First Large-Scale Longitudinal Nationwide Study on Management and Real-World Outcomes of Diabetes in India (LANDMARC)

R. Ghosh, A.K. Das, S. Joshi, A. Mithal, K.M. Prasanna Kumar, S. Kalra, A. Gopalakrishnan Unnikrishnan, H. Thacker, B. Sethi, S. Mohanasundaram, S.K. Menon, A. Nair, N. Rais, S. Kumar Wangnoo, S. Chowdhury, A.H. Zargar

2271-PUB: Rate of Diabetes Complications During the Initial 6 Months of the First Large-Scale Longitudinal Nationwide Study on Management and Real-World Outcomes of Diabetes in India (LANDMARC)

R. Ghosh, A.K. Das, S. Joshi, A. Mithal, K.M. Prasanna Kumar, S. Kalra, A. Gopalakrishnan Unnikrishnan, H. Thacker, B. Sethi, S. Mohanasundaram, S.K. Menon, A. Nair, N. Rais, S. Kumar Wangnoo, S. Chowdhury, A.H. Zargar

Back to top

Information is provided for scientific purposes only and may be outside the current labelling of the product. Sanofi does not recommend the use of any products in any manner inconsistent with that described in the full prescribing information. Please consult the prescribing information in your country of practice, as it can vary from country to country.

Availability of posters and/or abstracts on this site will coincide with ADA’s embargo policy.